It was found that CCR5 antagonists can disrupt TAM recruitment via the CCL5/CCR5 pathway, enhancing the clinical outcomes for various cancers, including gastric and pancreatic, by curbing tumor progression and extending patient survival157–159. The gene discussed is CCR5; the disease is neoplasm.